Athersys Inc. (ATHX) EVP Sells $29,400.00 in Stock
Athersys Inc. (NASDAQ:ATHX) EVP John J. Harrington sold 15,000 shares of Athersys stock in a transaction dated Friday, September 16th. The stock was sold at an average price of $1.96, for a total transaction of $29,400.00. Following the completion of the sale, the executive vice president now owns 619,639 shares of the company’s stock, valued at approximately $1,214,492.44. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Athersys Inc. (NASDAQ:ATHX) opened at 1.97 on Tuesday. The company’s market capitalization is $167.41 million. Athersys Inc. has a 12-month low of $0.94 and a 12-month high of $2.90. The firm has a 50-day moving average of $1.99 and a 200 day moving average of $2.19.
Athersys (NASDAQ:ATHX) last posted its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.10) by $0.02. Athersys had a negative net margin of 18.89% and a negative return on equity of 25.42%. The firm earned $0.60 million during the quarter, compared to analyst estimates of $0.32 million. During the same quarter in the prior year, the business posted ($0.05) EPS. The business’s revenue was up 200.0% compared to the same quarter last year. Analysts expect that Athersys Inc. will post ($0.21) EPS for the current fiscal year.
ATHX has been the subject of several analyst reports. TheStreet upgraded shares of Athersys from a “sell” rating to a “hold” rating in a research note on Tuesday, May 31st. Maxim Group reiterated a “buy” rating on shares of Athersys in a research note on Monday, September 12th. Finally, Zacks Investment Research upgraded shares of Athersys from a “hold” rating to a “buy” rating and set a $2.25 price objective for the company in a research note on Monday, August 15th.
Several hedge funds have recently bought and sold shares of ATHX. Vanguard Group Inc. raised its stake in Athersys by 5.6% in the second quarter. Vanguard Group Inc. now owns 3,221,130 shares of the biopharmaceutical company’s stock valued at $6,990,000 after buying an additional 171,330 shares during the last quarter. BlackRock Fund Advisors raised its position in Athersys by 822.9% in the second quarter. BlackRock Fund Advisors now owns 1,982,338 shares of the biopharmaceutical company’s stock valued at $4,302,000 after buying an additional 1,767,535 shares during the last quarter. State Street Corp raised its position in Athersys by 1,932.0% in the second quarter. State Street Corp now owns 1,046,480 shares of the biopharmaceutical company’s stock valued at $2,272,000 after buying an additional 994,980 shares during the last quarter. BlackRock Institutional Trust Company N.A. raised its position in Athersys by 190.0% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 859,172 shares of the biopharmaceutical company’s stock valued at $1,864,000 after buying an additional 562,950 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in Athersys by 204.0% in the first quarter. Renaissance Technologies LLC now owns 343,034 shares of the biopharmaceutical company’s stock valued at $772,000 after buying an additional 230,200 shares during the last quarter. Hedge funds and other institutional investors own 17.86% of the company’s stock.
Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.
Receive News & Ratings for Athersys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.